MTOR and cutaneous melanoma: As the mitogenic action through the AKT-mTOR pathway propels aerobic glycolysis more in skin melanoma cells than in RPE cells, the UVR- or UA-induced p53 activation can result in tumor glycolysis inhibition, leading to a metabolic switch from lactate fermentation to pyruvate oxidation, preferentially occurring in skin melanoma cells [18,118].